Home >
Medicine Info >
Bortenat 3.5 mg Injection
Loading interface...

Bortenat 3.5 mg Injection

Manufactured byNatco Pharma Ltd.
ContainsBortezomib
Description
Bortenat 3.5 mg Injection is an anticancer agent used in the treatment of multiple myeloma (a cancer of the bone marrow), and mantle cell lymphoma.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Substitutes

List of substitutes for Bortenat 3.5 mg Injection

Bortrac 3.5 mg Injection
Glenmark Pharmaceuticals Ltd.
Myezom 3.5 mg Injection
Dr. Reddys Laboratories Ltd.
Velcade 3.5 mg Injection
Janssen India

Side effects

Major & minor side effects for Bortenat 3.5 mg Injection

  • Weakness and general discomfort
  • Nausea and Vomiting
  • Diarrhea
  • Anxiety
  • Back pain
  • Muscle cramps
  • Difficulty in falling asleep
  • Headache
  • Anemia
  • Difficulty in breathing
  • Edema
  • Rash
  • Cough
  • Hypotension

Uses of Bortenat 3.5 mg Injection

What is it prescribed for?

  • Mantle Cell Lymphoma
  • Multiple Myeloma
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The time required for this medicine to show its effect is not clinically established.
  • How long do the effects of this medicine last?
    The time until which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is recommended for use in breastfeeding women only in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to bortezomib, boron, or mannitol.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is recommended for use in breastfeeding women only in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
General warnings

Diabetes

Bortenat 3.5 mg Injection may alter the blood glucose levels and may also increase the risk of new-onset diabetes mellitus. Close monitoring of blood glucose levels is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on clinical condition.

Dehydration

Bortenat 3.5 mg Injection should be used with caution due to the increased risk of dehydration. Report any symptoms such as dizziness, lightheadedness, fainting, muscle cramps, etc. to the doctor on priority. Appropriate corrective measures and dose adjustments may be necessary based on the clinical condition.

Heart disease

This medicine should be used with extreme caution in patients with a history of heart disease and active heart disease due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is advised during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Acute respiratory syndrome

This medicine should be used with caution in patients with a history of pulmonary diseases and active pulmonary diseases due to the increased risk of worsening of the patient's condition. Close monitoring of lung function is advised during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Blood cell count

This medicine may lower the white blood cell and platelet counts. Close monitoring of complete blood cell counts is necessary during treatment with this medicine. Appropriate dose adjustments should be done based on the clinical condition.

Missed Dose

If you miss an appointment to receive a dose of this medicine, contact your doctor immediately for further instructions.

Overdose

Since this medicine is administered by a qualified healthcare professional in the clinical or hospital setup, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Clozapine

Metformin

Nitrofurantoin

Insulin

Infliximab

Disease interactions

Cardiac Toxicity

Bortenat 3.5 mg Injection should be used with extreme caution in patients with cardiac diseases due to the increased risk of worsening of the patient's condition. Cardiac function should be assessed before initiating the treatment. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Hepatotoxicity

Bortenat 3.5 mg Injection should be used with extreme caution in patients with liver diseases due to the increased risk of worsening of the patient's condition. Liver function should be assessed before initiating the treatment. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Diabetes

This medicine should be used with caution in patients with diabetes due to the increased risk of altered blood glucose levels. Blood glucose levels should be monitored closely during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Hypotension

Bortenat 3.5 mg Injection should be used with extreme caution in patients with dehydration and patients on antihypertensive medicines due to the increased risk of hypotension. Blood pressure should be assessed before initiating the treatment. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Pulmonary toxicity

Bortenat 3.5 mg Injection should be used with extreme caution in patients with pulmonary dysfunction due to the increased risk of worsening of the patient's condition. Lung function should be assessed before initiating the treatment. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Carefully follow all the instructions given by your doctor. This medicine is given in multiple cycles. It is important to receive every scheduled dose and make a note of the next scheduled dose. Close monitoring of blood cell counts is necessary during treatment with this medicine. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works
Bortenat 3.5 mg Injection works by inhibiting the growth of cancer cells.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Proteasome inhibitors

Schedule

N/A

Bortezomib - DrugBank [Internet]. Drugbank.ca. 2017 [cited 31 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB00188

Bortezomib: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 31 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a607007.html

DailyMed - VELCADE - bortezomib injection, powder, lyophilized, for solution [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 31 August 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7

Prescribing medicines in pregnancy database [Internet]. Therapeutic Goods Administration (TGA). 2017 [cited 31 August 2017]. Available from:

https://www.tga.gov.au/prescribing-medicines-pregnancy-database

[Internet]. 2017 [cited 6 September 2017]. Available from:

http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 7 Sep 2017

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.